News archive search

Search the Newsreel

Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.

Showing
1–14
Matches
14
Sources here
9
Companies here
1
Search results Stored financial headlines

Active search

14 matching headlines

Ticker or company: AVLNMain company stories
Clear
Latest

MarketBeat Analyst action

Avalyn Pharma (NASDAQ:AVLN) Cut to Sell at Wall Street Zen

Wall Street Zen has downgraded Avalyn Pharma (NASDAQ:AVLN) from a "hold" to a "sell" rating, despite the overall analyst sentiment being a "Moderate Buy" with a $60 average price target. Other firms like Jefferies, Guggenheim, and Evercore have issued "buy" or "outperform" ratings, while Weiss Ratings also assigned a "sell (D+)." Avalyn Pharma's stock recently rose 7.3% to …

Main company 🇺🇸 United States
Read at MarketBeat
Sharemaestro market context Stored weekly price path 16 weeks +31.5% · Next-week setup negative 41.4% AVLN stored weekly price path from 1 May 2026 to 14 Aug 2026
Just inNext headlines
Stock Titan Deals and strategy Main company 🇺🇸 United States

Novo Holdings A/S (AVLN) discloses 8.8% beneficial stake in Avalyn Pharma

Novo Holdings A/S, an investment firm owned by the Novo Nordisk Foundation, has reported an 8.8% beneficial stake in Avalyn Pharma Inc. The firm holds 3,883,289 shares of Avalyn Pharma's voting common stock, with sole voting and dispositive power over these shares. The Novo …

AVLN main company
Sharemaestro market context Stored weekly price path 16 weeks +31.5% · Next-week setup negative 41.4% AVLN stored weekly price path from 1 May 2026 to 14 Aug 2026
MarketBeat Earnings Main company 🇺🇸 United States

Avalyn Pharma (NASDAQ:AVLN) Hits New 52-Week High Following Better-Than-Expected Earnings

Avalyn Pharma (NASDAQ:AVLN) shares reached a new 52-week high of $39.99 after reporting a quarterly loss of $0.98 per share, which surpassed analysts' expectations of a $1.03 loss. Analyst sentiment remains largely positive, with a consensus "Buy" rating and an average price target of …

AVLN main company
Sharemaestro market context Stored weekly price path 16 weeks +31.5% · Next-week setup negative 41.4% AVLN stored weekly price path from 1 May 2026 to 14 Aug 2026

Search results

Matching headlines

External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.

TradingView Earnings Main company 🇺🇸 United States

Avalyn Pharma Inc. Q2 2026: Net loss $(28.9M), EPS $(0.98) — 10-Q Summary

Avalyn Pharma Inc. reported a wider net loss of $(28.9M) in Q2 2026, compared to $(20.2M) in Q2 2025, with basic and diluted net loss per share at $(0.98). The clinical-stage biotech company continues to invest in its development programs, including AP01, AP02, and …

AVLN main company
Sharemaestro market context Stored weekly price path 16 weeks +31.5% · Next-week setup negative 41.4% AVLN stored weekly price path from 1 May 2026 to 14 Aug 2026
TradingView Earnings Main company 🇺🇸 United States

Avalyn Pharma reports Q2 2026 net loss $28.9M; cash $413.5M, runway into 2029

Avalyn Pharma reported a Q2 2026 net loss of $28.9 million, ending the period with $413.5 million in cash, which is projected to fund operations into 2029. The company saw increased R&D and G&A expenses due to clinical activity and headcount. Key business highlights …

AVLN main company
Sharemaestro market context Stored weekly price path 16 weeks +31.5% · Next-week setup negative 41.4% AVLN stored weekly price path from 1 May 2026 to 14 Aug 2026
Investing.com Canada Market update Main company 🇺🇸 United States

Form 8K Avalyn Pharma Inc. For: 12 August By Investing.com

This article reports that Avalyn Pharma Inc. has filed a Form 8K for August 12, as reported by Investing.com. The filing is brief and does not provide further details within the article content. It is categorized under stock market news.

AVLN main company
Sharemaestro market context Stored weekly price path 16 weeks +31.5% · Next-week setup negative 41.4% AVLN stored weekly price path from 1 May 2026 to 14 Aug 2026
GlobeNewswire Earnings Main company 🇺🇸 United States

Avalyn Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Avalyn Pharma Inc. announced its financial results for the second quarter ended June 30, 2026, and highlighted recent business achievements, including the completion of enrollment for its MIST global Phase 2b trial of AP01 with 398 patients. The company reported $413.5 million in cash, …

AVLN main company
Sharemaestro market context Stored weekly price path 16 weeks +31.5% · Next-week setup negative 41.4% AVLN stored weekly price path from 1 May 2026 to 14 Aug 2026
MarketBeat Analyst action Main company 🇺🇸 United States

Avalyn Pharma Inc. (NASDAQ:AVLN) Given Average Recommendation of "Buy" by Analysts

Five research firms have issued a consensus "Buy" rating for Avalyn Pharma Inc. (NASDAQ:AVLN), with an average 12-month price target of $59.00. The company recently reported a quarterly loss of $21.83 per share, missing analyst estimates, and currently has a market capitalization of $1.57 …

AVLN main company
Sharemaestro market context Stored weekly price path 16 weeks +31.5% · Next-week setup negative 41.4% AVLN stored weekly price path from 1 May 2026 to 14 Aug 2026
nasdaq.com Earnings Main company 🇺🇸 United States

Biotech Stocks At 52-Week Highs - HALO +20% On Q2 Results, FENC, AVLN, AMLX, CHE

(RTTNews) - The following biotech stocks reached 52-week highs on August 7, 2026, driven by key catalysts such as positive quarterly reports or upcoming clinical results. Halozyme Therapeutics Inc. (HALO) Halozyme is a biopharmaceutical company specializing in the production of proprietary enzymes and devices. …

AVLN main company
Sharemaestro market context Stored weekly price path 16 weeks +31.5% · Next-week setup negative 41.4% AVLN stored weekly price path from 1 May 2026 to 14 Aug 2026
MarketBeat Earnings Main company 🇺🇸 United States

Avalyn Pharma (NASDAQ:AVLN) Reaches New 52-Week High - Time to Buy?

Avalyn Pharma (NASDAQ:AVLN) recently hit a new 52-week high of $33.49, closing at $32.93, with a market capitalization of $1.47 billion. Analysts maintain a "Buy" rating with a consensus price target of $59, despite the company reporting a quarterly EPS loss that missed expectations. …

AVLN main company
Sharemaestro market context Stored weekly price path 16 weeks +31.5% · Next-week setup negative 41.4% AVLN stored weekly price path from 1 May 2026 to 14 Aug 2026
FinancialContent Earnings Main company 🇺🇸 United States

Avalyn Pharma Inc. - common stock (AVLN) Stock Price, News, Quote & History

This article provides stock information for Avalyn Pharma Inc. (AVLN), including its current price, recent trading activity, and key financial metrics. It also compiles recent news and press releases highlighting the company's progress in clinical trials for its inhaled pirfenidone (AP01) for pulmonary fibrosis, …

AVLN main company
Sharemaestro market context Stored weekly price path 16 weeks +31.5% · Next-week setup negative 41.4% AVLN stored weekly price path from 1 May 2026 to 14 Aug 2026

Find financial news

Search the Newsreel

Use one field or combine several. Results are newest first.

Evidence context